Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
Tetracaine hydrochloride is a local anesthetic ophthalmic solution approved by the FDA in 2016, delivered as a topical eye drop for use in ophthalmologic procedures and diagnostics. It works by blocking sodium channels in nerve fibers to produce local anesthesia of the cornea and conjunctiva. The drug is used primarily to anesthetize the eye prior to diagnostic procedures, minor surgical interventions, and tonometry.
The product is at peak commercial maturity with moderate competitive pressure (30% intensity), suggesting a stable but competitive market environment for field and brand teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on tetracaine hydrochloride positions you in a stable, operationally mature product within Alcon's ophthalmology portfolio, where success depends on relationship management, formulary penetration, and defending market share against generic and equivalent competitors. This role offers solid commercial fundamentals but limited opportunity for breakthrough innovation or exponential growth.
Worked on TETRACAINE HYDROCHLORIDE at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.